The Medicines Patent Pool
Governance Board Meeting 22

26-27 March, 2018
Geneva, Switzerland

Attendees

Governance Board Members:
Dr. Marie-Paule Kieny, Dr. Charles Clift, Ms. Jayashree Watal, Dr. Brian Tempest, Dr. Claudia Chamas, Ms. Anna Zakowicz, Dr. Anban Pillay, Dr. Manica Balasegaram, Dr. Patrizia Carlevaro

Absent: Dr. Brian Tempest

Non-voting members:
Mr. Akko Eleveld (Unitaid), Ms. Judith Polsky (Unitaid) (Day one only), Dr. Philippe Duneton (Unitaid) (Day 2 Only), Mr. Cees de Joncheere (vice-chair EAG)

Medicines Patent Pool Foundation Staff Members:
Ms. Alnaaze Nathoo, Ms. Asma Rehan, Mr. Vincent Chauvin, Mr. Sandeep Juneja, Ms. Katherine Moore, Mr. Chan Park, Mr. Esteban Burrone, Ms. Aastha Gupta, Dr. Diz Gotham*

* These individuals attended the afternoon session of the board meeting only.

Summary of Decisions

The Governance Board of the Medicines Patent Pool:

**Agenda item 1:**
- Approves and adopts the minutes from the 21st Board meeting
- Adopts the agenda of the 22nd Board meeting
- Approves the report for submission to the Office des Surveillance des Fondations and requests its title be changed to “MPP Annual Report”

**Agenda item 3:**
- Approves the 2017 Financial Statements
- Approves the 2017 auditor’s report

**Agenda item 4:**
On the recommendation of the Finance and Management Committee, the Board:
- Approves that the consultancy grid as proposed to be added to the Finance and Management Policy
- Approves the cancellation of all corporate credit cards except for the Chief Financial Officer, whose card is used for office expenditure and travel bookings.
c. Approves the modification of the Travel and Expense Policy to enable cash advance payments to support employees who travel.

d. Approves the allocation of the UN Perdiems (scaled as flights and accommodation are paid directly by the MPP) to employees and consultants for professional trips up to a maximum period of 5 days. From the 6th day of travel, employees will be reimbursed for actual costs.

e. Approves the cancellation of the 2,000 CHF limit on training costs per staff member and requests the CFO to identify, prioritize and present a list of training opportunities to be granted to staff in 2018. The Board requests the CFO to explore trainings and activities pertaining to staff leadership.

f. Approves the addition of the CFO in the list of authorized signatories and requests management to ensure that all signatures are collective.

g. Approves the risk matrix with the discussed adjustments. The Board recommends that risks which are red be reviewed at the next meeting. The Board agrees that management should continue to monitor the risks regularly, and any risks above the threshold of 6, be brought to the attention of the board.

Agenda item 5:
On the recommendation of the Ethics and Compliance Committee, the Board:

a. Approves that the definition of ‘significant other’ in the CoI policy be replaced by the term domestic partner, as was suggested in the last board meeting.

b. Approves the recommendation that MPP Board or EAG members may retain an interest in a Restricted Company but should not participate in discussions about, or with, that company. Staff members should not hold an interest in a Restricted Company, and new members will be asked to dispose of them.

c. Approves the recommendation that a member with an interest in a company, or a domestic partner with an interest, that becomes Restricted as a result of entering into a relationship with MPP shall be treated in a similar manner.

d. Approves the recommendation that EAG members need not undergo training because of their limited direct involvement in MPP day-to-day affairs but should, along with others, be provided with guidance on filling in the CoI Declaration form.

Agenda item 12:

a. Approves MPP’s expansion beyond its current mandate in HIV, TB and HCV.

b. The Board notes that the MPP should make a phased expansion, initially into small molecules listed in the WHO Model List of Essential Medicines as well as medicines with strong potential for future inclusion in view of their clinical benefits and potential for public health impact in low and middle-income countries.

c. The Board notes that the prioritization of products is the next step in expanding MPP’s model and requests management to identify priorities for in-licensing and present them at the next board meeting.

d. The Board acknowledges that IP is not the only barrier to access and requests the MPP to explore other possible interventions for facilitating access such as (a) facilitating technology transfer, (b) sharing of seed (starting) material, using (c) their projecting methodology (impact) to stimulate an interest in the market of orphan/widow (forgotten) drugs. The MPP, through its prioritization process, should remain vigilant of the next big drug/blockbuster.

Agenda item 13:
On the recommendation of the Strategy and Partnerships Committee, the Governance Board:

a. Approves the 2018-2022 strategic plan of the MPP, including the expansion beyond its current mandate in HIV, HCV and TB. In order to facilitate this expansion, the Board agrees that the MPP should continue to rely upon appropriate medical advice and adapt its current EAG to accommodate experts in other areas.